Gloria Ong, MD
Internal Medicine · Goodyear, AZNPI 1134570971
Payments from drug & device makers
Across 390 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$824
- AstraZeneca$450
- Pfizer$447
- Abbott$405
- Johnson & Johnson$307
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,116100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 101 | $1,177 |
| GSK | 82 | $824 |
| AstraZeneca | 29 | $450 |
| Pfizer | 25 | $447 |
| Abbott | 17 | $405 |
| Johnson & Johnson | 12 | $307 |
| Astellas Pharma US Inc | 11 | $288 |
| Boehringer Ingelheim | 14 | $274 |
| AbbVie(2 entities) | 14 | $256 |
| Sanofi-aventis U.S. LLC | 11 | $201 |
| Lilly USA, LLC | 9 | $125 |
| Medtronic | 6 | $121 |
| Amarin Pharma, Inc. | 6 | $108 |
| Biosense Webster, Inc. | 1 | $103 |
| Intuitive Surgical | 1 | $99 |
| Boston Scientific | 4 | $86 |
| Amgen | 4 | $82 |
| Merck | 5 | $78 |
| Bayer | 4 | $69 |
| Eisai Inc. | 3 | $61 |
| Inspire Medical Systems, Inc. | 3 | $59 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Novartis | 2 | $45 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Nabriva Therapeutics, PLC | 2 | $27 |
| Covis Pharma GmbH | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $24 |
| Mylan Specialty L.p. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Echosens North America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,116 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $122,698 |
| MounjaroTirzepatide | 42 | $51,977 |
| EliquisApixaban | 31 | $35,845 |
| FarxigaDapagliflozin Propanediol | 24 | $30,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $27,300 |
| TrulicityDulaglutide | 17 | $25,751 |
| JardianceEmpagliflozin | 18 | $24,849 |
| MyrbetriqMirabegron | 16 | $20,408 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,809 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 103 | $3,307 |
| Trazodone Hcl | 85 | $3,090 |
| Atorvastatin Calcium | 328 | $2,861 |
| Alendronate Sodium | 131 | $2,510 |
| Rosuvastatin Calcium | 162 | $2,200 |
| Losartan Potassium | 220 | $2,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,177 | $122,69895 claims |
| Lilly USA, LLCMounjaro, Trulicity | $125 | $77,72859 claims |
| PfizerEliquis | $447 | $35,84531 claims |
| AstraZenecaFarxiga, Symbicort | $450 | $34,08038 claims |
| GSKTrelegy Ellipta | $824 | $27,30023 claims |
| Boehringer IngelheimJardiance | $274 | $24,84918 claims |
| Astellas Pharma US IncMyrbetriq | $288 | $20,40816 claims |
| AbbVieSynthroid | $256 | $92037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Goodyear
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.